Clinical trials: Alzheimer Disease(AD)
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease
R21 Roche: 3-Way Tau Tracers in AD
This is an open label study to compare three new generation TAU radioligands, 18F-RO948 (formerly known as 18F-6958948), 18F-MK6240, and [18F]GTP1for imaging of taupathy and demonstrate their absence of off-target binding in…
- Trial name
- NCT05464368
- Testing
- [18F]RO-948, 18F-MK6240, 18F-GTP1
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
MCI-AD, Early Stage Alzheimer's Disease
Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI
As populations age, Alzheimer's disease (AD) is increasing while disease-modifying drugs remain elusive, making early diagnosis and intervention essential.
- Trial name
- NCT07196592
- Testing
- Olfactory stimulation, Temporal Interference,TI, Olfactory-TI Stimulation
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Yuan Shen
Alzheimer's Disease in Down Syndrome
Goal Attainment Scaling (GAS) Sub-Study
This is an optional sub-study that will enroll participants from LIFE-DSR parent protocol. The aim is to assess change over 16 months in individuals with Down syndrome through individualized goals set by their caregivers.
- Trial name
- NCT06484426
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- LuMind IDSC Foundation
Alzheimer's Disease
Oxaloacetate Pharmacokinetics and Safety
By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's disease who take OAA for one month have any…
- Trial name
- NCT02063308
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Russell Swerdlow, MD